13 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
with the implementation of our strategy and the growth of our business. In particular, the following are the principal risks which could cause a decline … and Mitigation Strategy (REMS) because of its: (1) poor oral availability requiring intravenous (or IV) or intranasal (or IN) administration, (2) ability
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
from the cannabis plant.
Our Strategy
Our goal is to develop therapeutics targeting well-characterized CB1 and CB2 receptors with optimized … pharmacological properties to transform the lives of patients with neurological diseases. Key elements of our strategy to achieve this goal include:
Advance
424B1
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus with pricing info
12:59pm
potentially provide a preferred alternative in such patient populations, as it is not derived from the cannabis plant.
Our Strategy
Our goal … with neurological diseases. Key elements of our strategy to achieve this goal include:
Advance MIRA1a through clinical development and approval.
Continue
S-1
EX-99.1
ffy3grepye5x dna5on
29 Jun 23
IPO registration
4:39pm
S-1
mcbeeoy43nwhv8o8a
29 Jun 23
IPO registration
4:39pm
DRS/A
3glr8aecfww8vbs
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-99.1
z3cbkhh
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
jg31bx s1de
2 May 23
Draft registration statement (amended)
12:00am
DRS
c9mcuwcj
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next